Actinium Pharmaceuticals, Inc. - FORM 10-K - EX-23.1 - CONSENT OF GBH CPAS, PC - March 16, 2018

Attached files

file filename
EX-10.60 - INDEMNIFICATION AGREEMENT, DATED FEBRUARY 8, 2018, BETWEEN ANIL KAPUR AND ACTINI - Actinium Pharmaceuticals, Inc.f10k2017ex10-60_actinium.htm
EX-10.57 - OFFER LETTER, EFFECTIVE JANUARY 2, 2018, BETWEEN DALE L. LUDWIG AND ACTINIUM PHA - Actinium Pharmaceuticals, Inc.f10k2017ex10-57_actinium.htm
EX-32.2 - CERTIFICATION - Actinium Pharmaceuticals, Inc.f10k2017ex32-2_actinium.htm
EX-32.1 - CERTIFICATION - Actinium Pharmaceuticals, Inc.f10k2017ex32-1_actinium.htm
EX-31.2 - CERTIFICATION - Actinium Pharmaceuticals, Inc.f10k2017ex31-2_actinium.htm
EX-31.1 - CERTIFICATION - Actinium Pharmaceuticals, Inc.f10k2017ex31-1_actinium.htm
EX-10.59 - OFFER LETTER, EFFECTIVE JANUARY 31, 2018, BETWEEN ANIL KAPUR AND ACTINIUM PHARMA - Actinium Pharmaceuticals, Inc.f10k2017ex10-59_actinium.htm
EX-10.58 - INDEMNIFICATION AGREEMENT, DATED JANUARY 5, 2018, BETWEEN DALE L. LUDWIG AND ACT - Actinium Pharmaceuticals, Inc.f10k2017ex10-58_actinium.htm
EX-10.56 - SIXTH AMENDMENT TO THE 2013 AMENDED AND RESTATED STOCK PLAN, AS AMENDED - Actinium Pharmaceuticals, Inc.f10k2017ex10-56_actinium.htm
10-K - ANNUAL REPORT - Actinium Pharmaceuticals, Inc.f10k2017_actiniumpharma.htm

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in the Registration Statement on Form S-3 (File No. 333-216748) and Form S-8 (File No. 333-216746 and File No. 333-197283) filed with the Securities and Exchange Commission, of our report dated March 16, 2018, relating to the consolidated financial statements of Actinium Pharmaceuticals, Inc. as of December 31, 2017 and 2016 and for each of the three years in the period ended December 31, 2017 and relating to the internal controls over financial reporting as of December 31, 2017, appearing in this Annual Report on Form 10-K of Actinium Pharmaceuticals, Inc.

  

/s/ GBH CPAs, PC

 

GBH CPAs, PC

www.gbhcpas.com

Houston, Texas

March 16, 2018

Actinium Pharmaceuticals, Inc. Reports

Also read